Moving to a Higher Dose of Wegovy: What to Expect

What a higher dose of Wegovy does differently in your body

Every Wegovy dose activates the same GLP-1 receptors, but the depth of that activation scales with the amount of semaglutide present. At lower doses (the 0.25mg and 0.5mg steps) the primary job is tolerability: your digestive system is adjusting to a medicine that slows how quickly food leaves the stomach. The appetite-reducing signal is there, but it is modest. As the dose climbs toward 1.7mg and 2.4mg (the previous standard maintenance level), the satiety effect becomes meaningfully stronger. Many people find they feel full on smaller portions, lose interest in food between meals, and experience fewer cravings overall.

The approved 7.2mg dose extends that curve further. The clinical evidence behind the 7.2mg approval showed that higher semaglutide concentrations produce a more sustained suppression of appetite and a greater overall reduction in body weight, roughly 20.7% on average over 72 weeks in the trials that supported the MHRA's decision. That figure sits close to the results seen with tirzepatide at 15mg, narrowing a gap that was once considered substantial.

One practical detail: gastric emptying slows more at higher doses, which affects how quickly other medicines and nutrients are absorbed. If you are on oral contraceptives, a prescriber will usually want to discuss this before any increase. Side effects also tend to be more noticeable immediately after a dose step, which is precisely why increases happen gradually rather than all at once.

The factors your prescriber weighs before increasing your dose

Dose titration is not a reward for good behaviour on a lower dose. It is a structured clinical assessment. Your prescriber will look at how much weight you have lost so far, how well you have tolerated the current dose, whether any side effects are still settling, and whether there are any changes to your health since the last review. Continuing treatment at 2.4mg or above when less than 5% of body weight has been lost after six months is a decision that NICE's guidance on semaglutide, TA875, says should be reviewed carefully, and the same logic applies to any higher dose step.

Some people reach a plateau at 2.4mg. Others tolerate it well but feel their appetite has not been suppressed as much as they hoped. Those are both reasonable grounds for a prescriber to consider the step to 7.2mg, provided the clinical picture supports it. The decision also depends on whether the higher-dose pen format is appropriate for you, the MHRA's April 2026 approval of the dedicated 7.2mg single-dose pen confirmed it is licensed for adults with a BMI of 30 or above, and if you are wondering what using a Wegovy dose higher than 2.4mg actually involves, the starting dose still begins at 0.25mg regardless of how long you have been on semaglutide previously if you are new to treatment.

Transfer patients who are already established at 2.4mg can, subject to prescriber assessment, move more directly toward the higher dose rather than restarting the entire ladder. That is a clinical judgement. If you are asking whether you can start on a higher dose of Wegovy, speak to our prescribers, who can assess your individual situation and advise where you stand.

What to realistically expect when you move up

The first few days after a dose increase are the most likely time for nausea, loose stools or fatigue to reappear, even if you sailed through earlier steps without difficulty. This is the same GI-led side-effect profile documented for semaglutide at every level, and for most people it settles within a week or two as the body acclimatises. The NHS semaglutide medicines page lists what to watch for and when symptoms warrant urgent attention.

In terms of weight loss, the additional reduction from moving to a higher dose tends to accumulate over weeks rather than appearing immediately. Realistic expectations matter here. The trial averages are exactly that (averages across a large study population) and individual results vary based on diet, activity, metabolic factors and how consistently the medicine is taken. A timing note worth considering: if you are planning ahead around holidays or a particularly disrupted month, your prescriber may factor that into when a dose increase makes sense, since adjusting mid-disruption can make it harder to distinguish tolerance issues from circumstantial ones.

Understanding what the evidence shows for higher-dose semaglutide more broadly can help you go into that prescriber conversation with the right questions already in mind. If you are weighing up whether Wegovy is the right treatment for you at all, our overview of weight-loss treatment options covers the alternatives too.

Starting the conversation about your next dose step

The right time to discuss a dose increase is when your current dose has had a proper run, usually at least four weeks at that level, with side effects that have settled rather than ones that are still active. Coming to that conversation with a sense of how your appetite, weight and tolerance have changed gives your prescriber the information they need to make a good call.

At nume, our clinical team reviews every repeat and dose-increase request personally before anything is approved or dispensed. There is no automated sign-off. If the evidence supports moving up, your updated treatment is dispatched the same day (for orders placed before 12pm, Monday to Friday) and arrives free the next working day. If there is a clinical reason to hold at the current dose a little longer, you will hear that clearly and why. Speak to our prescribers about where you are in your treatment and what the next step should look like for you.